News

Beginning June 3,2008, the Sagmel over-the-counter (OTC) business will become part of Bayer HealthCare in Russia, the Ukraine, Kazakhstan, the Baltic’s and several Caucasian and central Asian countries.

The trial assessed the safety and pharmacokinetics of NN7128 in 30 healthy subjects. In the trial a significant prolongation of the half-life of NN7128 was observed. Furthermore, single

Gracevit received approval for manufacture and marketing from the Japanese Ministry of Health, Labour and Welfare on January 25 and attained the National Health Insurance drug price listing

The primary objective of the Phase I study, which was conducted in Canada, was to determine the cutaneous and systemic toxicity of the topically-applied photoactive drug, SL017, with

The Impella 2.5 is cleared for use under the 510(k) for partial circulatory support for periods up to six hours. The intra-aortic balloon pump (IABP) also has 510(k)

APP’s new labeling represents further enhancements to help differentiate Heparin Sodium from other heparin products, including Heparin Lock Flush Solution, USP. Product with the new labeling will begin

The Phase I results showed that SJG-136 administered on a daily x 3 basis at 30micrograms/m2/day (recommended Phase II dosing) resulted in confirmed partial response as defined by

The Phase I clinical study tested escalating single doses of G4544 in 30 normal volunteers. The endpoints of the study were to determine safety and to assess pharmacokinetics

Zoraxel Phase II trial is a double-blind, placebo-controlled study. This multi-center trial is expected to be completed by the end of 2008. Zoraxel is being developed as an